Novel vancomycin free base - Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)

被引:0
|
作者
Nwabuife, Joshua C. [1 ]
Hassan, Daniel [1 ]
Pant, Amit Madhaorao [1 ]
Devnarain, Nikita [1 ]
Gafar, Mohammed Ali [1 ]
Osman, Nawras [1 ]
Rambharose, Sanjeev [2 ]
Govender, Thirumala [1 ]
机构
[1] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa
[2] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Bag X1 Matieland, ZA-7602 Stellenbosch, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Sterosomes; Novel delivery systems; Antimicrobial resistance; DRUG-DELIVERY SYSTEMS; IN-VITRO; NANOPARTICLES; ACID; NANOTECHNOLOGY; NANOSYSTEM; PATHOGENS; EFFICACY; POLYMER; BURDEN;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A clarion call to save antimicrobials is the need for the evolution of novel delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (S. aureus and MRSA) to con-ventional forms. Herein, we present a novel vancomycin free base - sterosomes (VCM-FB - Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB - Sterosomes were prepared using the thin-film hydration method and were characterised physiochemically, in silico, in vitro and in vivo. In vitro cytotoxicity on MCF-7 and HEK-293 cell lines were evaluated, with results revealing cell viability above 70% after exposure to VCM-FB - Sterosomes, indicating biosafety. VCM-FB - Sterosomes had a hydrodynamic diameter, polydispersity index and surface-charge of 114.14 +/- 0.59 nm, 0.210 +/- 0.02 and +36.3 +/- 5.42 mV, respectively, with entrapment efficiency, drug loading and VCM-FB release after 48 h of 79.61 +/- 0.59%, 90.91% w/w and 54.95 +/- 9.75% respectively. In silico studies showed a self-assembly in five nano seconds, which was stable thereafter. VCM-FB - Sterosomes were seen to be stable over 90 days and were also non-hemolytic. VCM-FB - Sterosomes showed a 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA, relative to bare VCM-FB, with MICs of 1.95 mu g/mL and 0.98 mu g/mL for VCM-FB and VCM-FB - Sterosomes (S. aureus), and 7.81 mu g/mL and 3.91 mu g/mL for VCM-FB and VCM-FB - Sterosomes (MRSA), respectively. A faster bacterial killing time was also recorded for VCM-FB - Sterosomes compared to bare VCM-FB. Greater MRSA membrane damage was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB - Sterosomes showed superior MRSA biofilm reduction (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed that VCM-FB - Sterosomes had significant MRSA eradication (27-fold) compared to bare VCM-FB (4-fold). These results amplify the superiority of VCM-FB - Sterosomes for S. aureus and MRSA infection treatment compared to conventional forms.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Methicillin-resistant Staphylococcus aureus (MRSA) in the Athlete
    Redziniak, D. E.
    Diduch, D. R.
    Turman, K.
    Hart, J.
    Grindstaff, T. L.
    MacKnight, J. M.
    Mistry, D. J.
    INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 2009, 30 (08) : 557 - 562
  • [22] Methicillin-resistant Staphylococcus aureus (MRSA) - diagnostics
    Linde, H
    Lehn, N
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (11) : 582 - 585
  • [23] MRSA: Methicillin-Resistant Staphylococcus aureus Foreword
    Leikin, Jerrold B.
    DM DISEASE-A-MONTH, 2008, 54 (12): : 750 - 750
  • [24] Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections
    Johnson, JR
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) : 236 - 237
  • [25] Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections
    Rahman, M
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (03) : 325 - 328
  • [26] Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
    Rod, Linda
    Hoyt, K. Sue
    ADVANCED EMERGENCY NURSING JOURNAL, 2007, 29 (02) : 118 - 128
  • [27] Prevalence and antibiotyping of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in domestic animals in India
    Yadav, Ritika
    Kumar, Amit
    Singh, Vinod K.
    Jayshree
    Yadav, Sharad K.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 15 : 222 - 225
  • [28] Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
    Micek, Scott T.
    CLINICAL INFECTIOUS DISEASES, 2007, 45 : S184 - S190
  • [29] Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?
    Mostofsky, Elizabeth
    Lipsitch, Marc
    Regev-Yochay, Gili
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (10) : 2199 - 2214
  • [30] Vancomycin Heteroresistance and Methicillin-Resistant Staphylococcus aureus
    Deresinski, Stan
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (05): : 605 - 609